Adjuvant portal liver infusion in colorectal cancer with 5‐fluorouracil/heparin versus urokinase versus control results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

This prospectively randomized clinical trial was carried out in four Dutch hospitals to reduce the development of metachronous liver metastases and to get a better survival in patients with colorectal malignancies after surgically radical en bloc resection of the primary tumor and the regional lymph nodes. Three hundred seventeen patients were randomized to participate in three trial arms. One group of patients was treated by surgery alone (control group); in the other patients a catheter was placed in the dilated umbilical vein and advanced until the tip was lying in the left branch of the portal vein. Fifty percent of these patients got immediate postoperative portal infusion with 1 g 5‐fluorouracil (5‐FU) and 5000 U heparin daily for 7 days; the others received portal vein infusion with urokinase 10,000 U/hour for 24 hours only. Three hundred four patients were eligible. Overall hospital mortality was 3.6% (11 patients) and was not influenced by adjuvant treatment. After a median follow‐up of 44 months 66 patients have died with relapse and 21 as a result of other causes. The chance of developing liver metastases and other distant metastases after portal infusion with 5‐FU/heparin was one third of the chance in the control group (P < 0.001). Only an insignificant reduction of the average death rate in the 5‐FU/heparin group was found. In the urokinase group no significant effect in reducing metastases or in survival was noted. Before recommending cytotoxic portal infusion as an adjuvant treatment in patients with colorectal cancer, detailed analysis of other ongoing portal infusion studies has to be awaited and careful calculations have to be made regarding how many patients really can be saved by this treatment.

[1]  J. Arends,et al.  No‐Touch isolation technique in colon cancer: A controlled prospective trial , 1988, The British journal of surgery.

[2]  P. Mcculloch,et al.  Warfarin inhibition of metastasis: The role of anticoagulation , 1987, The British journal of surgery.

[3]  P. Bell,et al.  Five year results of a randomized trial of adjuvant 5‐fluorouracil and levamisole in colorectal cancer , 1987, The British journal of surgery.

[4]  J. Jass,et al.  Role of urokinase in colorectal neoplasia , 1987, The British journal of surgery.

[5]  B. Shenton,et al.  Effect of perioperative blood transfusion on recurrence of colorectal cancer , 1986, The British journal of surgery.

[6]  D. Machin,et al.  A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer , 1985, The British journal of surgery.

[7]  W. Henderson,et al.  Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 , 1984, Cancer.

[8]  V. Devita.  The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer , 1983, Cancer.

[9]  E. Salzman,et al.  Effect of perioperative low-dose heparin administration on the course of colon cancer. , 1983, Surgery.

[10]  S. Moss,et al.  Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial. , 1981, The Surgical clinics of North America.

[11]  I. Taylor,et al.  The British Journal of Surgery , 2022 .

[12]  Tony M. Plant,et al.  Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone , 1979 .

[13]  A. B. Barnes,et al.  Comparison of Histologic and Colposcopic Findings in DES-Exposed Females , 1978, Obstetrics and gynecology.

[14]  I. Taylor,et al.  Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. , 1977, British medical journal.

[15]  B. Cedermark,et al.  The value of liver scan in the follow-up study of patients with adenocarcinoma of the colon and rectum. , 1977, Surgery, gynecology & obstetrics.

[16]  P. Whittle,et al.  Further studies on the industrial melanic moth Biston betularia (L.) in the northwest of the British Isles , 1976, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[17]  P. Hilgard,et al.  Anticoagulants in the treatment of cancer. , 1976, European journal of cancer.

[18]  J. Griffiths,et al.  Circulating Malignant Cells and Fibrinolysis during Resection of Colorectal Cancer , 1976, Proceedings of the Royal Society of Medicine.

[19]  W. Regelson,et al.  Chemotherapy as an Adjuvant to Surgery for Colorectal Cancer , 1975, Annals of surgery.

[20]  F. Schabel.  Concepts for systemic treatment of micrometastases , 1975, Cancer.

[21]  J. Griffiths,et al.  Fibrinolysis and circulating malignant cells. , 1973, Surgery, gynecology & obstetrics.

[22]  J. Griffiths,et al.  Carcinoma of the colon and rectum: Circulating malignant cells and five‐year survival , 1973, Cancer.

[23]  S Bengmark,et al.  The natural history of primary and secondary malignant tumors of the liver I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy , 1969, Cancer.

[24]  F. R. Watson,et al.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates. , 1967, Annals of surgery.

[25]  W. Garvie.  Studies on induced tumour resistance , 1966, The British journal of surgery.

[26]  E. Cliffton,et al.  Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism , 1962, Cancer.

[27]  O. Jonasson,et al.  Clinical significance of cancer cells in the circulating blood: two- to five-year survival. , 1961 .

[28]  Robert R. Smith,et al.  The time of metastasis and release of circulating tumor cells as determined in an experimental system , 1961, Cancer.

[29]  B. Fisher,et al.  Experimental Studies of Factors Influencing Hepatic Metastases: III. Effect of Surgical Trauma with Special Reference to Liver Injury , 1959, Annals of surgery.

[30]  W. Cole,et al.  The Prophylactic Treatment of Cancer at the Time of Operation , 1957, Annals of surgery.

[31]  G. Higgins,et al.  Efficacy of prolonged intermittent therapy with combined 5‐fluorouracil and methyl‐ccnu following resection for carcinoma of the large bowel. A veterans administration surgical oncology group report , 1984, Cancer.

[32]  Å. Rieger,et al.  The influence of heparin and curable resection on the survival of colorectal cancer. , 1983, Acta chirurgica Scandinavica.

[33]  B. Gustavsson,et al.  Concentration of biologically active 5-fluorouracil in general circulation during continuous portal infusion in man: a preliminary report. , 1975, Cancer letters.

[34]  D. Cox.  Regression Models and Life-Tables , 1972 .

[35]  E. Cliffton,et al.  THE EFFECTS OF FIBRIN FORMATION AND ALTERATIONS IN THE CLOTTING MECHANISM ON THE DEVELOPMENT OF METASTASES. , 1965, Vascular diseases.